PDCD1 and Miyoshi myopathy: Nowadays, the 30% long-term survivors with anti-PD1 monotherapy and the 50% with anti-CTLA4 plus anti-PD1 combination, are emblematic of how immunotherapy has changed the prognostic landscape of MM [2].